Valneva (NASDAQ:VALN) Shares Gap Up to $7.51

Valneva SE (NASDAQ:VALN)’s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $7.51, but opened at $7.71. Valneva shares last traded at $7.72, with a volume of 704 shares trading hands.

Analysts Set New Price Targets

A number of brokerages recently issued reports on VALN. HC Wainwright reissued a “buy” rating and set a $26.00 price target on shares of Valneva in a report on Monday, June 24th. Guggenheim dropped their target price on Valneva from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, March 22nd.

Valneva Trading Up 2.9 %

The firm has a market capitalization of $539.01 million, a price-to-earnings ratio of -18.33 and a beta of 2.20. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.22 and a current ratio of 2.64. The company has a 50 day moving average price of $7.86 and a two-hundred day moving average price of $8.02.

Valneva (NASDAQ:VALN) last released its earnings results on Tuesday, May 7th. The company reported $0.89 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.12. Valneva had a negative net margin of 15.88% and a negative return on equity of 14.56%. The business had revenue of $35.56 million during the quarter, compared to analysts’ expectations of $95.80 million. On average, research analysts forecast that Valneva SE will post -0.56 EPS for the current year.

Institutional Trading of Valneva

A hedge fund recently raised its stake in Valneva stock. General American Investors Co. Inc. grew its holdings in shares of Valneva SE (NASDAQ:VALN) by 2.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 354,361 shares of the company’s stock after purchasing an additional 9,361 shares during the quarter. General American Investors Co. Inc. owned approximately 0.51% of Valneva worth $2,831,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.